Q BioMed Inc., a commercial stage biotech company, has completed a financial restructuring of approximately $7.8 million with its lead investor, Yorkville Advisors Global (YA).

This restructuring of debt and new capital will provide for the company to implement its full commercial plan as it brings its FDA approved non-opioid, Strontium89 Chloride USP Injection drug to market. 

Denis Corin, QBioMed CEO said, “In addition to the rollout of our Strontium89 drug, this funding allows us to advance other key pipeline assets such as our infectious disease platform including a potential treatment for COVID-19, influenza and others, liver cancer therapy Uttroside B and our rare disease drug development in non-verbal autism spectrum disorders.”